Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8410)	5/19/2003 3:08:42 PM
From: scaram(o)uche	Respond to of 52153

Low hanging fruit.... insulin, growth hormone, erythropoeitin and G-CSF..... they drove a sustained period of investment that lasted until '93, and then also drove much of the optimism '95-'98. IMO, epo is the key player...... AMGN carved enough away from JNJ, and was a two product company for what seemed like ages. Huge culture areas, devoted to roller bottles! We all laughed. Until we didn't. Pharmaceutical margins and all, extended to biologicals. AMGN carved out a big chunk of revenue AND a gold rush. In a way, the rush ended in (or, perhaps that's near-term perspective...... at very least, "was severely dented by" if not "ended in") the bubble offerings from HGSI and Celera. Parallel to epo? Just saying that it's perhaps another biological that will change the look of both medicine and business. If so, then it is inevitable that it would also lead to a relatively sustained investor interest.